SCHEMBL374497

SCHEMBL374497

Nc1ccc(OCCN2CCOCC2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.67
PTGS1 P23219 1/20 0.67
PTGS2 P35354 1/20 0.67
CA12 O43570 1/20 0.67
CA1 P00915 1/20 0.67
CA2 P00918 1/20 0.67
CA7 P43166 1/20 0.67
CA9 Q16790 1/20 0.67
NPC1 O15118 1/20 0.66
RAB9A P51151 1/20 0.66
ALDH1A1 P00352 3/20 0.62
MAPK1 P28482 2/20 0.62
CYP1A2 P05177 1/20 0.62
CHRM2 P08172 1/20 0.62
CHRM1 P11229 1/20 0.62
HTR2A P28223 1/20 0.62
SCN1A P35498 1/20 0.62
HTR2B P41595 1/20 0.62
KCNH2 Q12809 1/20 0.62
SCN2A Q99250 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2385707 0.98 NPC1 (0.68) LTA4HPTGS1PTGS2CA12CA1
SCHEMBL14204158 0.98 CA12 (0.65) LTA4HPTGS1PTGS2CA12CA1
Hydrochloric Acid SCHEMBL14742325 0.98 NPC1 (0.68) LTA4HPTGS1PTGS2CA12CA1
SCHEMBL3398830 0.95 LTA4H (0.75) LTA4HPTGS1PTGS2CA12CA1
SCHEMBL18763470 0.93 CA12 (0.59) LTA4HPTGS1PTGS2CA12CA1
SCHEMBL374569 0.92 HRH3 (0.74) CA12CA1CA2CA7CA9
SCHEMBL24398699 0.91 TSHR (0.76) LTA4HPTGS1PTGS2CA12CA1
SCHEMBL28126773 0.90 HRH3 (0.68) NPC1RAB9AALDH1A1MAPK1CYP1A2
SCHEMBL16314572 0.89 ALDH1A1 (0.66) NPC1RAB9AALDH1A1MAPK1CYP1A2
SCHEMBL14724514 0.88 HRH3 (0.71) NPC1RAB9AALDH1A1MAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130030171-A1 Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors NOVARTIS AG (CH) 2013-01-31 US claimed
US-20080312248-A1 Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors NOVARTIS AG 2008-12-18 US claimed
EP-1976847-A2 PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS Novartis AG (CH) 2008-10-08 EP claimed
WO-2007071752-A2 PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS NOVARTIS AG (CH) 2007-06-28 WO claimed
EP-4640769-A1 CONDUCTIVE POLYMER-CONTAINING DISPERSION, SOLID ELECTROLYTE CAPACITOR, AND PRODUCTION METHOD FOR SAME Resonac Corporation (JP) 2025-10-29 EP disclosed
US-12278061-B1 Conductive polymer-containing dispersion liquid, solid electrolytic capacitor and method for producing same RESONAC CORPORATION (JP) 2025-04-15 US disclosed
US-20250118500-A1 CONDUCTIVE POLYMER-CONTAINING DISPERSION LIQUID, SOLID ELECTROLYTIC CAPACITOR AND METHOD FOR PRODUCING SAME RESONAC CORPORATION (JP) 2025-04-10 US disclosed
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 EP disclosed
US-20250069818-A1 METHOD FOR PRODUCING POLYMER DISPERSION FOR SOLID ELECTROLYTIC CAPACITOR, AND METHOD FOR PRODUCING SOLID ELECTROLYTIC CAPACITOR RESONAC CORPORATION (JP) 2025-02-27 US disclosed
EP-4466258-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-11-27 EP disclosed
EP-4466259-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-11-27 EP disclosed
US-20240383875-A1 Benzimidazole Pyridine Derivatives HOFFMANN-LA ROCHE INC. (US) 2024-11-21 US disclosed
US-6479488-B1 GOOD IN VITRO AFFINITY FOR THE STRYCHNINE INSENSITIVE GLYCINE BINDING SITE ASSOCIATED WITH THE NMDA RECEPTOR COMPLEX BUT ALSO GOOD IN VIVO ACTIVITY WHEN ADMINISTERED SYSTEMICALLY GLAXO WELLCOME SPA (IT) 2002-11-12 US disclosed
EP-0922034-B1 TETRAHYDROQUINOLINE DERIVATIVES AS EAA ANTAGONISTS GLAXO WELLCOME SPA (IT) 2002-07-24 EP disclosed
EP-0922034-A1 TETRAHYDROQUINOLINE DERIVATIVES AS EAA ANTAGONISTS GLAXO WELLCOME S.p.A. (IT) 1999-06-16 EP disclosed
WO-1998007704-A1 TETRAHYDROQUINOLINE DERIVATIVES AS EAA ANTAGONISTS GLAXO WELLCOME S.P.A. (IT) 1998-02-26 WO disclosed
EP-0410358-B1 AROMATIC CARBOXYLIC ACID AMIDES, THEIR PREPARATION AND THEIR USE AS MEDICINES F. HOFFMANN-LA ROCHE AG (CH) 1993-09-29 EP disclosed
US-5216153-A Therapy and prophylaxis for skin, autoimmune and rheumatic diseases HOFFMANN-LA ROCHE INC. (US) 1993-06-01 US disclosed
US-5128470-A Aantiinflammatory, antiallergens HOFFMANN-LA ROCHE INC. (US) 1992-07-07 US disclosed
EP-0410358-A1 Aromatic carboxylic acid amides, their preparation and their use as medicines F. HOFFMANN-LA ROCHE AG (CH) 1991-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312248-A1 Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors FGFR1, FGF1, FGF2 LTA4H 3869/4885PTGS1 814/4885PTGS2 895/4885
US-20240383875-A1 Benzimidazole Pyridine Derivatives H1-3, H1-2, H1-4 LTA4H 2346/4885PTGS1 542/4885PTGS2 723/4885
US-20130030171-A1 Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors FGFR1, FGF1, FGF2 LTA4H 3869/4885PTGS1 814/4885PTGS2 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.